Tophi (Gout): A Complete Patient‑Friendly Guide

Overview

Tophi are deposits of monosodium urate (MSU) crystals that form under the skin, around joints, or in soft tissues in people with longstanding or severe gout. While gout itself is an acute arthritis caused by hyperuricemia (elevated blood uric acid), tophi represent the chronic, destructive phase of the disease.

Who it affects

• Adults older than 40 years are most commonly affected, but gout can occur at any age.
• Men develop gout 3–4 times more often than women; after menopause, women’s risk approaches that of men.
• People with chronic kidney disease, metabolic syndrome, or a family history of gout are at higher risk.

Prevalence

• In the United States, gout affects ~4% of adults (≈8.3 million people) ^[1].
• Up to 15%–20% of patients with longstanding gout develop visible tophi ^[2].
• Incidence is rising worldwide, linked to increased obesity, high‑purine diets, and the use of diuretics.

Symptoms

Tophi may be painless at first, but as they grow they can cause pain, functional limitation, and cosmetic concerns. Symptoms often coexist with the typical gout attacks.

Local Symptoms

• Subcutaneous nodules – firm, yellow‑white or chalky deposits, most often on the:
  • ears (helix),
  • elbows (olecranon),
  • knees,
  • fingers, toes, and especially the first metatarsophalangeal (MTP) joint.
• Pain or tenderness – especially when a tophus ruptures or becomes inflamed.
• Swelling and erythema – may mimic infection; the skin over a tophus can become thin and ulcerate.
• Restricted range of motion – large tophi can interfere with joint movement, leading to stiffness.

Systemic Symptoms

• Recurrent gout flares (sudden, severe joint pain, often at night).
• Fever or chills if a tophus becomes infected (rare but serious).

Signs of Complication

• Skin breakdown or ulceration over a tophus.
• Excessive bleeding from a ruptured tophus.
• Joint deformity and chronic pain.

Causes and Risk Factors

Tophi are the result of chronic hyperuricemia—persistent uric acid levels above the solubility threshold (~6.8 mg/dL). When uric acid exceeds this limit, crystals precipitate in tissues.

Main Causes

• Overproduction of uric acid – due to high‑purine diets (red meat, seafood, organ meats), excessive alcohol (especially beer), fructose‑rich drinks.
• Under‑excretion of uric acid – the most common cause; kidneys fail to eliminate urate efficiently.
• Genetic predisposition – variants in genes such as SLC2A9 and ABCG2 affect urate transport.

Risk Factors

• Male sex, age > 40 years.
• Obesity (BMI ≥ 30 kg/m²) – adipose tissue increases urate production and reduces renal clearance.
• Chronic kidney disease (eGFR < 60 mL/min/1.73 m²).
• Hypertension and use of thiazide or loop diuretics.
• Metabolic syndrome (high triglycerides, low HDL, insulin resistance).
• High‑purine diet, heavy alcohol consumption, sugary beverages.
• Recent rapid reduction of uric‑lowering therapy (can trigger “tophi flare”).
• Family history of gout or hyperuricemia.

Diagnosis

Diagnosing tophaceous gout combines clinical assessment, laboratory testing, and imaging.

Clinical Evaluation

• Physical exam for characteristic nodules (chalky, firm, sometimes fluctuating).
• History of recurrent gout flares or known hyperuricemia.

Laboratory Tests

• Serum uric acid – levels > 6.8 mg/dL support the diagnosis, but patients can be normouricemic during an acute flare.
• Inflammatory markers (ESR, CRP) – often elevated during active inflammation.
• Joint aspiration (arthrocentesis) – gold standard; identification of negatively birefringent MSU crystals under polarized light microscopy confirms gout.
• Synovial fluid analysis also rules out septic arthritis.

Imaging

• Ultrasound – shows the “double contour” sign (urate crystal deposition on cartilage) and tophus size.
• Dual‑energy CT (DECT) – specifically differentiates urate crystals from calcium, providing a map of tophaceous burden ^[3].
• Conventional X‑ray – may reveal erosions with overhanging edges (punched‑out lesions) typical of chronic gout.

Diagnostic Criteria

The 2015 ACR/EULAR classification criteria for gout assign points for clinical, laboratory, and imaging findings. A total score ≥8 classifies gout, and the presence of tophi adds points automatically.

Treatment Options

Treatment aims to (1) control acute inflammation, (2) lower serum urate to dissolve existing tophi, and (3) prevent new crystal formation.

Pharmacologic Therapy

1. Acute Attack Management

• NSAIDs (e.g., naproxen, indomethacin) – first‑line unless contraindicated.
• Colchicine – loading dose 1.2 mg then 0.6 mg; useful within 24 h of symptom onset.
• Corticosteroids – oral prednisone 30 mg daily taper or intra‑articular injection for refractory cases.

2. Urate‑Lowering Therapy (ULT)

ULT is essential for tophus resolution. Initiation is recommended once serum urate ≥ 6.8 mg/dL and especially when tophi are present.

• Allopurinol – xanthine oxidase inhibitor; start 100 mg daily, titrate to target urate <6 mg/dL.
• Febuxostat – alternative for allopurinol‑intolerant patients; 40–80 mg daily.
• Probenecid – uricosuric agent; useful when renal function is adequate (eGFR > 30 mL/min).
• Lesinurad – combined with a xanthine oxidase inhibitor to enhance uric acid excretion.
• Pegloticase – intravenous recombinant uricase for refractory gout with extensive tophi; rapid urate reduction, but infusion reactions can occur.

**Target serum urate:** ≤ 5 mg/dL for patients with tophi (per ACR guidelines) to promote faster crystal dissolution ^[4].

3. Anti‑inflammatory Prophylaxis

• Low‑dose colchicine (0.6 mg daily) or NSAID for the first 3–6 months after starting ULT to prevent flare‑ups.

Procedural and Surgical Options

• Intralesional corticosteroid injection – can shrink inflamed tophi.
• Surgical excision – indicated for:
  • Functional impairment (e.g., tendon rupture).
  • Skin ulceration or infection.
  • Cosmetic concerns when nodules are large and exposed.
• Debulking arthroscopy – for intra‑articular tophi causing mechanical block.

Lifestyle and Dietary Modifications

• Limit purine‑rich foods: red meat, organ meats, anchovies, sardines, mussels.
• Reduce alcohol intake, especially beer and spirits.
• Limit fructose‑sweetened beverages; aim for ≤ 1 L of water per day to facilitate uric acid excretion.
• Maintain a healthy BMI (goal < 25 kg/m²).
• Increase low‑fat dairy and plant‑based proteins (beans, peas).
• Discuss vitamin C supplementation (500 mg daily) – modest urate‑lowering effect ^[5].

Living with Tophi (Gout)

Managing tophaceous gout is a long‑term commitment. Below are practical tips for daily life.

Medication Adherence

• Take ULT consistently, even when you feel well. Set daily reminders.
• Track serum uric acid with periodic labs (every 2–3 months until stable, then every 6–12 months).

Skin Care

• Keep tophi clean and dry; use mild soap and pat gently.
• Apply protective dressings if the skin is thin or ulcerated.
• Avoid tight clothing or footwear that compresses the nodules.

Exercise & Mobility

• Low‑impact activities (walking, swimming, cycling) preserve joint function without stressing affected joints.
• Strengthen surrounding muscles with physical therapy; this can reduce pain and improve balance.
• Warm‑up before activity and stretch after to limit stiffness.

Weight Management

• Aim for gradual weight loss (0.5–1 kg/week); rapid loss can transiently raise uric acid.
• Consider a registered dietitian for personalized meal planning.

Monitoring for Flare‑Ups

• Recognize early signs: sudden warmth, throbbing pain, swelling around a tophus.
• Start prescribed NSAID or colchicine at the first hint of a flare; early treatment shortens duration.

Psychosocial Support

• Visible tophi can affect self‑image; counseling or support groups can be beneficial.
• Share your condition with close friends/family so they can assist during severe attacks.

Prevention

Preventing tophi relies on early control of hyperuricemia and lifestyle choices.

• Screen high‑risk individuals (obese, hypertensive, CKD) with serum urate testing.
• Start urate‑lowering therapy early after the first gout attack if serum urate > 9 mg/dL or if there are risk factors for rapid progression.
• Adopt the dietary habits listed above.
• Stay hydrated (≥ 2 L water daily unless contraindicated).
• Review medications with your doctor; alternative antihypertensives (e.g., losartan) are less urate‑raising.
• Maintain regular follow‑up with a rheumatologist or primary care provider.

Complications

If left untreated, tophaceous gout can lead to serious, sometimes irreversible problems.

• Joint destruction – erosions and deformities leading to chronic pain and reduced mobility.
• Tendon rupture – especially the Achilles tendon when a tophus infiltrates it.
• Kidney stones – uric acid stones are more common in gout patients.
• Tophus infection (septic tophitis) – bacterial invasion can cause cellulitis, abscess, or sepsis.
• Skin ulceration & bleeding – overlying skin can break, leading to secondary infection.
• Reduced quality of life – chronic pain, functional limitation, and psychosocial distress.

When to Seek Emergency Care

---

References

1. Mayo Clinic. “Gout.” Updated 2023. https://www.mayoclinic.org/…
2. Cleveland Clinic. “Tophi – Gout Complications.” 2022. https://my.clevelandclinic.org/…
3. Dalbeth N, et al. “Dual‑energy CT in gout: Clinical utility.” *Arthritis Rheumatology*. 2021;73(8):1382‑1390.
4. American College of Rheumatology/European League Against Rheumatism. “2015 Gout Classification Criteria.” *Ann Rheum Dis*. 2015;74(10):1939‑1945.
5. Li C, Hsieh MC, et al. “Vitamin C and serum uric acid: a systematic review.” *J Clin Rheumatol*. 2020;26(5):229‑235.